or
forgot password

Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors


N/A
N/A
N/A
Not Enrolling
Both
Lymphoma, Non-Hodgkin

Thank you

Trial Information

Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors


Non-Hodgkin's lymphoma has been studied in the Pediatric Branch for at least 20 years,
during which time a number of different treatment protocols have been used. Approximately
110 patients have apparently been cured of their lymphoma. The present protocol has no
therapeutic component, but is designed to document the late effects that may have been
encountered by our patients, either as a consequence of the disease or its treatment. In
essence, patients who consent to participate will be asked a series of questions pertaining
to the quality of their life and possible medical problems that they may be encountering.
In addition, they will receive a complete physical examination and undergo non-invasive
investigations designed to identify the presence of unsuspected late effects. Investigators
in the Eye Clinic, Dental Clinic, Audiology, Cardiology and Endocrinology departments will
participate in the protocol. As a part of the study, blood samples will be obtained to
investigate the possibility that predisposing genetic factors may be identifiable in the
patients normal cells (e.g., p53 mutations, evidence of DNA instability). If such
abnormalities are detected, blood samples from family members will also be examined to
determine whether the defect was inherited.

Inclusion Criteria


Patients with a histologic diagnosis of small noncleaved cell (undifferentiated) (SNCL),
lymphoblastic (LL), and large cell lymphoma (LCL) who were treated according to National
Cancer Institute Pediatric Branch non-Hodgkin's lymphoma protocols 74-0, 75-6, 76-5,
77-04, 85-C-67, and 89-C-41A, and who have been in continuous remission for one year or
longer following completion of treatment.

Patients who have relapsed and been successfully re-treated are not excluded, except for
patients with lymphoblastic lymphoma who have been re-treated according to acute
lymphoblastic leukemia protocols.

Type of Study:

Observational

Study Design:

N/A

Authority:

United States: Federal Government

Study ID:

920242

NCT ID:

NCT00001301

Start Date:

August 1992

Completion Date:

April 2000

Related Keywords:

  • Lymphoma, Non-Hodgkin
  • Adverse Effects
  • Burkitt's Lymphoma
  • Diffuse Large Cell Lymphoma
  • Extended Remission
  • Health Status
  • Lymphoblastic Lymphoma
  • Molecular Studies
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location

National Cancer Institute (NCI) Bethesda, Maryland  20892